Company Overview of Shasun Pharmaceuticals Ltd
Shasun Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and enteric coating excipients. The company offers API products in the areas of pain management and musculoskeletal, central nervous system, cardiovascular, hyperphosphataemia, anti-infective, gastrointestinal, gastrointestinal, and other areas, as well as is developing API products in the areas of anti-depressant and anti-Parkinson’s. It is also engaged in the contract research and manufacturing services business, which provides chemistry and analytical services; and offers formulation development and manufacturing services for solid dosage products to pharmaceutical customers. In ...
3rd & 4th Floor
28, Sardar Patel Road
Founded in 1976
Key Executives for Shasun Pharmaceuticals Ltd
Managing Director, Chief Executive Officer, Wholetime Director, Member of Stakeholders Relationship Committee and Member of Risk Management Committee
Total Annual Compensation: $10.1M
Whole-Time Director and Member of Corporate Social Responsibility Committee
Total Annual Compensation: $6.5M
Wholetime Director and Member of Audit Committee
Total Annual Compensation: $6.4M
Compensation as of Fiscal Year 2014.
Shasun Pharmaceuticals Ltd Key Developments
Shasun Pharmaceuticals Ltd Announces the Resignation of Indira J. Parikh as Independent Director
Feb 5 15
Shasun Pharmaceuticals Ltd. announced that the Board of Directors of the company at its meeting held on February 05, 2015, approved the resignation of Prof. Indira J. Parikh, Independent Director from the Board with effect from February 05, 2015.
Shasun Pharmaceuticals Ltd Announces Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014
Feb 5 15
Shasun Pharmaceuticals Ltd. announced unaudited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, on consolidated basis, the company's net sales/income from operations was INR 3,100.5 million compared with INR 3,093.8 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 209.2 million compared with INR 203.7 million a year ago. Profit from ordinary activities before tax was INR 68.1 million compared with INR 129.6 million a year ago. Net profit was INR 61.4 million or INR 0.99 per diluted share compared with INR 130.4 million or INR 2.30 per diluted share a year ago. EBITDA was INR 398.3 million compared with INR 441.8 million a year ago.
For the nine months, on consolidated basis, the company's net sales/income from operations was INR 9,158.5 million compared with INR 8,110.9 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 350.0 million compared with INR 174.3 million a year ago. Profit from ordinary activities before tax was INR 31.2 million compared with INR 95.1 million a year ago. Net profit was INR 16.0 million or INR 0.26 per diluted share compared with INR 198.1 million or INR 3.50 per diluted share a year ago. EBITDA was INR 873.2 million compared with INR 942.9 million a year ago.
For the quarter, on standalone basis, the company's revenue was INR 2,732.9 million compared with INR 2,465.4 million a year ago. EBITDA was INR 465.6 million compared with INR 338.3 million a year ago. PAT was INR 191.0 million compared with INR 101.2 million a year ago.
For the nine months, on standalone basis, the company's revenue was INR 8,032.8 million compared with INR 6,457.3 million a year ago. EBITDA was INR 1,028.3 million compared with INR 735.5 million a year ago. PAT was INR 344.4 million compared with INR 241.7 million a year ago.
Shasun Pharmaceuticals Ltd to Report Q3, 2015 Results on Feb 05, 2015
Jan 23 15
Shasun Pharmaceuticals Ltd announced that they will report Q3, 2015 results on Feb 05, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
February 7, 2015
|Alivira Animal Health Ltd.
December 31, 2014
September 29, 2014